ArticleScientific reports2024
All-optical 3D blue phase photonic crystal switch with photosensitive dopants.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 14 citations in OpenAlex.
- New Insights into Polymeric Liquid Crystals and Their Applications.Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Blue phase (BP) liquid crystals (LC) have lately become the focus of extensive research due to their peculiar properties and structure. BPs exhibit a highly organized 3D structure with a lattice period in the hundreds of nm. Owing to such structure, BPs are regarded as 3D photonic crystals. The unique properties of this complex LC phase are achieved by the self-assembly of the LC molecules into periodic cubic structures, producing bright selective Bragg reflections. Novel applications involving 3D photonic crystals would certainly benefit from enhanced ground-breaking functionalities. However, the use of BPs as 3D has been traditionally curtailed by the BP crystals trend to grow as random polycrystals, making it difficult to develop practical BP-based photonic devices. The possibility of generating mm-sized BP monocrystals was recently demonstrated. However, besides increasing the scarce number of 3D photonic structural materials, their applications as 3D photonic crystals do not show apparent advantages over other solid materials or metamaterials. Having a tunable BP monocrystal, where crystals could be switched, modulating simultaneously some of their properties as 3D photonic crystals, they would constitute a new family of materials with superior performance to other existing materials, opening up a plethora of new applications. In this work, an all-optical switchable 3D photonic crystal based on BPs doped with tailored photoactive molecules is demonstrated. Two switching modes have been achieved, one where the BP reversibly transitions between two BP phases, BPI and BPII, (two different cubic crystal systems) while maintaining the monocrystallinity of the whole system. The second mode, again reversible, switches between BPI and isotropic state. None of these modes are related to the regular thermal transitions between LC phases; switching is triggered by light pulses of different wavelengths. This all-optical approach allows for a seamless fast remotely controlled optical switch between two 3D photonic crystals in different cubic crystal systems and between a photonic crystal and an isotropic matrix. Applications of switchable BPs for adaptive optics systems or photonic integrated circuits would make great advances using 3D photonic crystal switches. All-optical photonic systems such as these hold great promise for the development of tunable and efficient photonic devices such as dynamic optical filters and sensors, as they enable light-driven modulation and sensing applications with unprecedented versatility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.